Latest News and Press Releases

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, is...

Providence, RI, June 10, 2025 (GLOBE NEWSWIRE) -- The nonprofit Association of Migraine Disorders is changing the conversation around migraine disease through its global Shades for Migraine...

Claimable Honored in Fast Company’s 2025 World Changing Ideas Awards. Recognition comes as Claimable expands its impact with support for GLP-1 appeals.

Series B funding round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in...

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one...

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a...

Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran...

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial...

ROCKAWAY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...